Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

New hope in global fight against antibiotic resistant superbugs

January 22, 2021August 16, 2022 Alterity Therapeutics

New hope in global fight against antibiotic resistant superbugs

2021

Post navigation

Alterity participates in world’s largest virtual healthcare conference JP Morgan

Quarterly Cash Flow Report

Related Posts

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

February 1, 2024February 1, 2024

Prana receives $3 million R&D Tax Incentive Refund

December 19, 2017August 16, 2022

Prana’s Founding Scientist and CSA publishes landmark paper in Nature

October 12, 2014August 16, 2022

Recent Posts

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065